EA202190755A1 - Агенты для терапии и диагностики рака - Google Patents

Агенты для терапии и диагностики рака

Info

Publication number
EA202190755A1
EA202190755A1 EA202190755A EA202190755A EA202190755A1 EA 202190755 A1 EA202190755 A1 EA 202190755A1 EA 202190755 A EA202190755 A EA 202190755A EA 202190755 A EA202190755 A EA 202190755A EA 202190755 A1 EA202190755 A1 EA 202190755A1
Authority
EA
Eurasian Patent Office
Prior art keywords
diagnosis
agents
cancer therapy
compounds
cxcr4
Prior art date
Application number
EA202190755A
Other languages
English (en)
Inventor
Тереза Осль
Ханс-Юрген Вестер
Маргрет Шоттелиус
Original Assignee
Технише Универзитет Мюнхен
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Технише Универзитет Мюнхен filed Critical Технише Универзитет Мюнхен
Publication of EA202190755A1 publication Critical patent/EA202190755A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/50—Cyclic peptides containing at least one abnormal peptide link
    • C07K7/52—Cyclic peptides containing at least one abnormal peptide link with only normal peptide links in the ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0056—Peptides, proteins, polyamino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids

Abstract

Настоящее изобретение относится к визуализации и эндолучевой терапии заболеваний, связанных с хемокиновым рецептором 4 (CXCR4). Предложены соединения, которые связывают или ингибируют CXCR4 и, кроме того, несут по меньшей мере один фрагмент, который может быть помечен. Также предложено медицинское применение таких соединений.
EA202190755A 2018-09-12 2019-09-11 Агенты для терапии и диагностики рака EA202190755A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP18194121 2018-09-12
PCT/EP2019/074195 WO2020053255A1 (en) 2018-09-12 2019-09-11 Therapeutic and diagnostic agents for cancer

Publications (1)

Publication Number Publication Date
EA202190755A1 true EA202190755A1 (ru) 2021-06-11

Family

ID=63579109

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202190755A EA202190755A1 (ru) 2018-09-12 2019-09-11 Агенты для терапии и диагностики рака

Country Status (3)

Country Link
US (1) US11639373B2 (ru)
EA (1) EA202190755A1 (ru)
WO (1) WO2020053255A1 (ru)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4043041A1 (en) 2021-02-15 2022-08-17 Technische Universität München Cxcr4-ligands for diagnostic and therapeutic use and precursors thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5308829B2 (ja) 2006-02-27 2013-10-09 テクニッシュ ユニべルシタット ミュンヘン 癌の画像化および処置
TWI412367B (zh) * 2006-12-28 2013-10-21 Medarex Llc 化學鏈接劑與可裂解基質以及其之綴合物
MY149432A (en) 2007-05-30 2013-08-30 Lilly Co Eli Cyclic peptide cxcr4 antagonists
GB0716897D0 (en) 2007-08-30 2007-10-10 Univ Muenchen Tech Cancer imaging and treatment
IT1397901B1 (it) 2010-01-26 2013-02-04 Consiglio Nazionale Ricerche Peptidi ciclici che legano il recettore cxcr4 e relativi usi in campo medico e diagnostico.
EP2380597A1 (en) 2010-04-20 2011-10-26 Technische Universität München Cyclopeptide derivatives and uses thereof
EP2380596A1 (en) 2010-04-20 2011-10-26 Technische Universität München Cyclopentapeptide derivatives and uses thereof
CN106573959B (zh) 2014-06-06 2022-03-25 慕尼黑工业大学 修饰的环五肽及其用途

Also Published As

Publication number Publication date
US11639373B2 (en) 2023-05-02
US20220041674A1 (en) 2022-02-10
WO2020053255A1 (en) 2020-03-19

Similar Documents

Publication Publication Date Title
MA47313B1 (fr) Formulations sous-cutanées d'anticorps her2
EA202091587A1 (ru) Анти-tigit антитела и их применение в качестве терапевтических и диагностических средств
BR112018070676A2 (pt) construtos de ligação a antígeno multiespecífico que têm como alvo agentes imunoterapêuticos
CY1126152T1 (el) Ενωσεις-αναστολεις της rip1 και μεθοδοι παρασκευης και χρησης αυτων
WO2016187220A3 (en) Anti-ror1 antibodies
MA38380A1 (fr) Inhibiteurs quinazoline de l'activation des formes mutantes du récepteur de croissance épidermique (egfr)
BR112022004986A2 (pt) Anticorpos anti-tnfr2 e métodos de uso
MA39725B1 (fr) Compositions pharmaceutiques de composés thérapeutiquement actifs
EA202191175A1 (ru) Сконструированные с цистеином конъюгаты антитело-лекарственное средство, содержащие пептидсодержащие линкеры
CL2018000131A1 (es) Inmunoconjugados de il22
JOP20200135A1 (ar) مركبات psma الترابطية للتصوير والعلاج الإشعاعي الداخلي
EA202092085A1 (ru) ТЕРАПЕВТИЧЕСКИЕ АНТИТЕЛА ПРОТИВ sPLA2-GIB И ИХ ПРИМЕНЕНИЕ
EA202191478A1 (ru) Гетероароматические соединения в качестве ингибиторов ванина
MX2022001841A (es) Anticuerpos contra ilt2 y uso de los mismos.
EA202190588A1 (ru) Гетероароматические соединения в качестве ингибиторов ванина
MY197419A (en) Psma-targeted radiopharmaceutical for diagnosing and treating prostate cancer
EA202190755A1 (ru) Агенты для терапии и диагностики рака
PH12021551174A1 (en) Novel folr1 specific binding proteins for cancer diagnosis and treatment
EA202192488A1 (ru) Антитела против tsg-6 и их применения
PH12020551912A1 (en) Use for preventing and treating myeloid-derived suppressor cell-related diseases
MX2021005751A (es) Anticuerpos contra mucina 16 y métodos de uso de los mismos.
MA54276B1 (fr) Montélukast destinée au traitement de l'arthrose de la main
MA39448A1 (fr) (r)-pirlindole et ses sels pharmaceutiquement acceptables destinés à un usage médical
EA202191477A1 (ru) Гетероароматические соединения в качестве ингибиторов ванина
EA201992852A1 (ru) Схема дозирования тезетаксела и капецитабина